Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2568)	8/28/2009 2:23:16 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

TRBN was up 76.2% and it is still up 45.95% at present.<g> Volume of 276,400 is about 23x its ADV. The stock opened with a good UG and traded above its Jul28 H of $4.23 bigcharts.marketwatch.com It announced an agreement with FACET for the joint worldwide development and commercialization of TRU-016, which is on a PI for CLL. TRBN will receive an upfront payment of $20M and may receive up to $176.5M in additional contingent payments.Facet will also purchase 2,243,649 shares of a newly issued TBRN common stock for an aggregate purchase price of $10M.<g>(The companies will share equally the costs of all development, commercialization and promotional activities and all global operating profits.) The stock is trying to get off from the DT coming from its March 2008 H at $12.60 bigcharts.marketwatch.com TRBN longer term resistance remains at the !5 to its Feb2007 all time H of $22.50 <g> bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (2568)	1/8/2010 3:40:40 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

IMMU is trying to rally after forming a good base at the $3.10 level.<g> bigcharts.marketwatch.com It announced today that its patent for "Immunotherapy of autoimmune disorders using antibodies which target B-cells" has been issued as U.S. patent no. 7,641,901. The patent covers the use of monoclonal antibodies that bind to the CD22 antigen on B-lymphocytes for treating autoimmune disorders. The stock is up 26.61% with volume now > 17M. It seems it could get to 10x its ADV since there is a good amount of short covering. (The SI was up 20% and about 6.7x the ADV <g>) The allowed claims cover the use of epratuzumab, its proprietary humanized anti-CD22 monoclonal antibody, and other anti-CD22 antibodies, alone and in combination with other therapeutics, such as antibodies, cytokines, or drugs, for the treatment of a wide range of autoimmune diseases that include systemic lupus erythematosus, rheumatoid arthritis, Sjogren's syndrome, multiple sclerosis, myasthenia gravis, diabetes mellitus, and ulcerative colitis. The resistance to watch is at the $5 to $5.10 level.<g> bigcharts.marketwatch.com Bernard